Amgen stock resistance test: Breakout levels to watch

Traders Union
All News
Stocks
Amgen jumps 4.72% after earnings beat

Highlights

Amgen stock surged after reporting second-quarter adjusted EPS of $6.29 and $10.1 billion in revenue, beating expectations.
The company raised its full-year 2026 revenue outlook, increased its dividend by 6%, and posted 10% product sales growth, driving investor optimism.
AMGN exhibits a strong bullish technical structure with persistent buying momentum and a projected trading range of $396.34 to $422.32 over the next few days.

Upbeat earnings and guidance fuel increased institutional demand

Amgen Inc. reported second-quarter 2026 results that surpassed expectations, with adjusted earnings per share of $6.29 and revenue of $10.1 billion signaling robust demand and strong operational execution, according to Investing.com. Building on this momentum, the company raised its full-year 2026 revenue guidance, which has further improved market sentiment around future earnings potential. Additionally, Amgen announced a 6% increase in its quarterly dividend and achieved 10% year-over-year product sales growth across its extensive portfolio, while advancing its MariTide obesity treatment program with multiple Phase 3 trials. These developments collectively drive heightened buying interest in the stock.

Technical breakout with momentum signals and overbought warning

The current price action is supported by a decisive break above key technical levels, with AMGN trading well above the MA-20 at $384.96, the MA-50 at $385.58, and the longer-term MA-200 at $344.74. The Ichimoku Kijun is positioned at $395.42, acting as immediate support. Momentum indicators are robust, as both MACD and ADX confirm sustained buying strength. Overbought signals from the RSI (83.01), Stochastic RSI, CCI, and Bull/Bear Power highlight the dominance of buyers but indicate the risk of a short-term pullback. The Awesome Oscillator aligns with the bullish trend, reflecting pronounced upward momentum.

Potential consolidation or breakout as volatility defines range

Looking ahead, the anticipated short-term range is between $396.34 and $422.32 over the next several sessions. The baseline scenario sees price consolidating within this band, with a very high likelihood of further gains and a sharp upward move possible if resistance is breached. Conversely, if the price falls below immediate support, a short-lived correction could occur despite the generally positive structure. This range reflects typical volatility relative to current market levels.

Anton Kharitonov, expert at Traders Union, sees Amgen’s strong Q2 fundamentals and guidance upgrade as supportive, but he remains wary of overextended technicals and stretched sentiment. Momentum indicators confirm current strength, yet extreme overbought readings highlight short-term pullback risk. He notes that the base case is consolidation and stability as long as support levels hold. "Unless we see a decisive break of support, I remain cautious despite the bullish news flow."

Previously it was reported that Amgen maintained a bullish technical outlook, with upward momentum supported by key trend indicators. The current breakout to new highs and raised company guidance further reinforce this positive stance, with the prevailing scenario suggesting attention should focus on the $396.34–$422.32 range for potential continuation or a near-term pullback.

Source of Data: AMGN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.